

Prof. Dr. med. Jochen Greiner

Chefarzt Hämatologie, Onkologie,
Palliativmedizin und Schmerztherapie
Medizinische Klinik
Diakonie-Klinikum Stuttgart



Kontakt

Prof. Dr. med. Jochen Greiner
Chefarzt für Hämatologie, Onkologie, Palliativmedizin und
Schmerztherapie

Diakonie-Klinikum Stuttgart
Rosenbergstraße 38
70176 Stuttgart

Telefon: 0711 991-3501
Telefax: 0711 991-3591

greiner@diak-stuttgart.de
www.diakonie-klinikum.de

Leiter Forschungsgruppe Tumorimmunologie Ulm
Klinik für Innere Medizin III
Universitätsklinikum Ulm

Helmholtzstraße 10
89081 Ulm

Telefon 0731-1506754

jochen.greiner@uniklinik-ulm.de

Lebenslauf/Curriculum Vitae

Persönliche Angaben

Geboren am 16.12.1970 in Reutlingen

Familienstand

Verheiratet, 2 Kinder

Akademische Laufbahn

1992-1998	Studium der Humanmedizin an der Eberhard-Karls-Universität Tübingen
1998	Promotion am Universitätsklinikum Tübingen (Note: magna cum laude) bei Professor Dr. med. C.D. Claussen und Professor Dr. P. Schweizer
01/99-06/00	Arzt im Praktikum am Universitätsklinikum Ulm, Klinik für Innere Medizin III. Ärztlicher Direktor: Professor Dr. med. H. Döhner
01.07.2000	Voll-Approbation
07/00-09/06	Wissenschaftlicher Mitarbeiter und Assistenzarzt am Universitätsklinikum Ulm, Klinik für Innere Medizin III
07/2006	Facharzt für Innere Medizin
10.10.2006	Habilitation an der Medizinischen Fakultät der Universität Ulm im Fach Innere Medizin mit dem Thema: „Identifizierung und Charakterisierung von Leukämie-assoziierten Antigenen“
01.08.2007	Facharzt für Hämatologie und internistische Onkologie
10/06-07/08	Organisation und Leitung des Leukämie- und Lymphomboards, sowie des Thoraxboards am neu gegründeten Comprehensive Cancer Centers Ulm (CCCU)
Seit 10/2006	Verantwortlicher ärztlicher Referent der Klinik für Innere Medizin III für verschiedene Tumorboards
Seit 04/2008	Ernennung zum Oberarzt der Klinik für Innere Medizin III Stationäre klinische Zuständigkeit vorwiegend für die Schleusenstationen M4C und M4D, sowie KMT-Station. Schwerpunkt: Akute Leukämien sowie autologe und allogene Stammzelltransplantationen.
Seit 10/2008	Leitung der Studienzentrale und DRG-Gruppe der Klinik Innere Medizin III
12.11.2008	Fachgebietsbezeichnung Palliativmedizin
Seit 06/2008	Leitung der Arbeitsgruppe Tumorimmunologie
12/2009	Sachkundige Person für eine Impfherstellung gemäß §15 AMG
12.02.2009	Anerkennung außerplanmäßige Professur (APL-Professur)
Seit 01/2010	Mitglied des Habilitationsausschusses der Medizinischen Fakultät der Universität Ulm

- 03/10-12/11 Erneute Organisation und Leitung des Thoraxboards des Comprehensive Cancer Centers Ulm (CCCU)
- Seit 09/2010 Personalverantwortung für die Erstellung des Rotationsplans der Klinik für Innere Medizin III und Einteilung der ärztlichen Mitarbeiter für das interne Curriculum zur hämato-onkologischen Facharztausbildung
- 09/2010 Verleihung des Jose Carreras Career Award
- 11/10-07/13 KMT-Ambulanz-Team, wöchentliche KMT-Ambulanz
- 01/2013 Sektionsleiter Onkologie in der Klinik für Innere Medizin III, Prof. Dr. H. Döhner
- 07/2013 Chefarzt für Hämatologie, Onkologie, Palliativmedizin und Schmerztherapie am Diakonie-Klinikum Stuttgart
- 07/2013 Gastwissenschaftler am Universitätsklinikum Ulm (Klinik für Innere Medizin III, Prof. Dr. H. Döhner) Leiter der Tumorimmunologie-Gruppe Ulm

Studienerfahrung bei klinischen Studien als Principle Investigator

- IMP 27335 (AS703569), phase I study, AML/MDS/CML
- Polyvalent peptide vaccination trial in patients with haematological malignancies, phase I/II, AML/MDS/MM/CLL
- NiloRAD/CAMN107ADE01, phase I/II, AML
- CLASSIC I (CLO34100405), phase III, AML
- BAY 43-9006, phase II, renal cell cancer
- CCI 404, phase II, renal cell carcinoma
- CA163-163, phase II, Non-Small Cell Lung Cancer
- A6181120, phase III, prostate cancer
- 111727(WT1-ASO1B-AML-002), phase I/II, AML
- STAR-TOR, phase IV, renal cell cancer
- Quolitax, phase IV, lung cancer
- CA180-227, phase III, prostate cancer
- BCA – Immunbio, non-investigational, Non-Small Cell Lung Cancer
- Mission study, BAY 43-9006 (sorafenib), phase II, Non-Small Cell Lung Cancer
- CESAR C-II-006, phase II, renal cell carcinoma
- Switch Study, phase III, renal cell carcinoma
- MAGRIT, phase II, Non-Small Cell Lung Cancer
- IMA 901-301, phase III, renal cell carcinoma
- UL-CMV-1, phase I, after allogeneic stem cell transplantation
- CLDK378X2101, phase I, Non-Small Cell Lung Cancer

Studienerfahrung bei klinischen Studien als Prüfarzt

- RHAMM-R3 peptide vaccination, phase I/II, AML/MDS/MM/CLL
- PXD101-CLN-15, phase I study, AML
- BI 1216.20 Protocol, phase I Study, AML
- AURA003, phase I Study, AML, CML
- C-LS 104-1101, phase I Study, AML, CML, MDS, CMPS
- AE-RC-99-02, renal cell carcinoma
- BI 1247.3, phase I Study, AML
- BI1230.4, phase I Study, AML
- NOA-08, phase III Study, Glioblastoma
- AMLSG 05-04, phase III, AML
- AMLSG 06-04, phase III, AML
- AMLSG 07-04, phase III, AML

- EURO-B.O.S.S, phase III, sarcoma
- CALGB 10603/ CTSU C10603, Ratify, phase III, AML
- Amgen 20060392, phase I/II, MDS
- AMLSG 10/07, phase I/II, AML
- Enzastaurin (LY317615), phase III Study, Glioblastoma
- STARs 20060392, phase I/II, observation, Breast, Prostate, or Lung Cancer
- Romiplostim (20060198), phase II, MDS
- APL 0406, phase III, AML
- AMLSG 11-08, phase Ib/IIa, AML
- AML BI 1230.4, phase I/IIa, AML
- AMLSG 08-07, phase I, AML
- AMLSG 09-09, phase I, AML
- RATGAA07, phase I, Aplastic anaemia
- CLBH589B2116, phase I/II, AML
- CLBH589G2101, phase Ib, AML
- Valena-Study, phase II, MDS
- LE-MON-5, phase II, MDS
- GEPARD, phase II, MDS
- Ewing 2008, phase III, Sarcoma
- H6Q-MC-S039, phase II, Glioblastoma
- CC-5013-CLL-509, phase II, CLL
- IELSG PCNSL, phase II, aggressive ZNS lymphoma
- SPRINT, phase III, mantle cell lymphoma
- DSMM XIII, phase II, multiple myeloma
- DSMM XII, phase II, multiple myeloma
- DSMM 0279, phase I/II, multiple myeloma
- CLBH589D2308, phase III, multiple myeloma
- SAHA-1, phase II, sarcoma
- MT 103-203, phase II, ALL
- MT 103-206, phase II, ALL
- Main B020603, phase III, diffuse large B cell lymphoma
- CLL11, phase III, CLL
- CLL20, phase II, CLL
- PMA 112509, phase I/II, MDS,AML
- AMLSG 12-09, phase II, AML
- AC220-002, phase II, AML
- AZA-AML001, phase III, AML
- GO-MORE - P06129, phase III, Rheuma

- CONTINUUM - CC-5013-CLL-002, phase III, CLL
- EFC6663, phase III, CLL
- MC-PEGASP.1, phase I/II, ALL
- CLAVIS 4055-306, phase III, AML
- PACET-CUP, phase II, CUP
- B021000 GAUDI, phase II, NHL
- CAL 101-09, phase II, NHL
- GMALL PH01, phase II, ALL
- EWALL-PH-02, phase II, ALL
- MT103-211, phase II, ALL
- CLAVELA CP4055-306, phase III, AML
- CC-5013-MCL-002, phase II, NHL
- CA 204004, phase III, multiple myeloma
- CA 204006, phase III, multiple myeloma
- PCYC-1104-CA, phase II, NHL
- AMLSG 14-09, phase II, AML
- AMLSG 15-10, phase III, AML
- CC-4047-MM-003, phase III, multiple myeloma
- CC-4047-MM-003/3, phase III, multiple myeloma
- ARD12130, phase II, NHL
- CLL2S, phase I/II, CLL
- GLARIUS-Studie, Glioblastom
- OMB110928, phase II, FL
- PAPAGEMO (AIO-ST5-009), phase II, sarcoma
- EAP/JUMP/CINC424A2401, expanded access, MPN
- RESPONSE, phase III, MPN
- OPTIMAL, phase III, aggressive B-NHL
- TransVax™, a Therapeutic DNA Vaccine for Control of Cytomegalovirus in Hematopoietic Cell Transplant Recipients, Phase III Clinical Trial, after allogeneic stem cell transplantation
- TK008: "Randomized phase III trial of haploidentical HCT with or without an add back strategy of HSV-TK donor lymphocytes" after allogeneic stem cell transplantation

Wissenschaftliche Förderungen

- NOVARTIS-Stiftung, „Charakterisierung von immunogenen Leukämie-assoziierten Antigenen bei myeloischer Leukämien“. Laufzeit: 2001–2003. Antragsteller: Dr. J. Greiner, Dr. M. Schmitt. Fördersumme: 180.000 Euro
- Anschubfinanzierung "Baustein-Förderung" der Universität Ulm. "Nachweis einer spezifischen zellulären Immunantwort gegen die neu identifizierten tumor-assoziierten Antigene RHAMM, MAZ und MPP11 bei leukämischen Blasten", Laufzeit 01/2002 bis 04/2004. Antragsteller: Dr. J. Greiner. Fördersumme: 70.000 Euro
- Deutsche José Carreras Leukämie-Stiftung e.V. "Charakterisierung von Antigenen bei der akuten myeloischen Leukämie". Zelluläre Assays für bereits definierte Leukämie-Antigene. Laufzeit bis einschl. 2003–2005. Antragsteller: Dr. M. Schmitt, Dr. J. Greiner, Dr. M. Wiesneth, Prof. Dr. H. Döhner. Fördersumme: 185.000 Euro
- Deutsche Forschungsgemeinschaft (DFG) „Rolle des Rezeptors für Hyaluronsäure-vermittelte Motilität (RHAMM/CD168) bei der Proliferation myeloischer Blasten“. Antragsteller: Dr. J. Greiner, PD Dr. M. Schmitt. Beginn der Förderung bis 2005–2007. Fördersumme: 185.900 Euro
- Deutsche José Carreras Leukämie-Stiftung e.V. „Entwicklung einer Polyvalenten Peptidvakzinierung für Patienten mit malignen hämatologischen Erkrankungen“. Laufzeit 07/2007–06/2009. Antragsteller: PD Dr. J. Greiner, Prof. Dr. M. Schmitt, Dr. M. Wiesneth, Prof. Dr. H. Schrezenmeier. Fördersumme: 178.000 Euro
- Else Kröner-Fresenius-Stiftung „Peptid-Vakzinierung für Patienten mit Chronischer Lymphatischer Leukämie“. Laufzeit 07/2007–06/2009. Antragsteller: Prof. Dr. M. Schmitt, PD Dr. J. Greiner, Dr. K. Giannopoulos. Fördersumme: 121.000 Euro
- BMBF-Förderung des Antrages „Präventive und therapeutische Peptid-Vakzinierung gegen HCMV“ im Rahmen des Aufbaus einer Forschergruppe in der klinischen Infektiologie „Erkennung, Vermeidung und Behandlung von Infektionen des immunkompromittierten Patienten“. Laufzeit 2007–2010; Projektleiter: Prof. Dr. J. Greiner. Fördersumme: 474.300 Euro
- Forschungsförderung „kooperative Reserach – Celgene“; „Evaluation des immunmodulatorischen Effektes von Lenalidomid/Revlimid® auf zytotoxische und regulatorische T-Zellen bei Patienten nach allogener Stammzelltransplantation. Antragsteller : PD Dr. J. Greiner; Laufzeit 2009–2010. Fördersumme: 39.000 Euro

- Deutsche José Carreras Leukämie-Stiftung e.V. „Einfluss Leukämie-assoziiertes Antigene auf die Zellproliferation myeloischer Blasten und auf das Überleben von Patienten mit akuter myeloischer Leukämie“. Beginn ab 01/2009. Antragsteller: Prof. Dr. J. Greiner, PD Dr. L. Bullinger. Fördersumme: 202.800 Euro
- Deutsche José Carreras Leukämie-Stiftung e.V. „Vakzine-verstärkte Spenderlymphozyten“. Laufzeit 10/2010–09/2012. Antragsteller: Prof. Dr. J. Greiner, Prof. Dr. M. Schmitt, Dr. M. Wiesneth, Prof. Dr. H. Schrezenmeier. Fördersumme: 259.000 Euro
- Jose Carreras Career Award 2010 der Deutschen José Carreras Leukämie-Stiftung e.V. „Weiterentwicklung immunologischer Behandlungsansätze für eine zielgerichtete Immuntherapie von Leukämien“. Beginn ab 09/2010. Fördersumme: 135.000 Euro
- Deutsche Forschungsgemeinschaft (DFG), "Immunogenität mutations-spezifischer Peptidsequenzen bei der akuten myeloischen Leukämie" Beginn ab 02/2011, 3 Jahre, Antragsteller: Prof. Dr. J. Greiner, Dr. S. Hofmann. Fördersumme: 235.000 Euro
- Else Kröner-Fresenius-Stiftung "Untersuchung der Immunogenität von Leukämie-Stammzellen bei der akuten myeloischen Leukämie (AML)". Beginn ab 09/2011 für 3 Jahre. Antragsteller: Prof. Dr. J. Greiner, Frau Vanessa Schneider. Fördersumme: 162.000 Euro

Gutachtentätigkeit für Journale

Blood

Journal of Clinical Oncology

Leukemia

PLOSone

Leukemia Research

Clinical Cancer Research

Biomarker Insights

Haematologica

Int J Cancer

Publikationsliste

1. Greiner J, Schneider V, Schmitt M, Götz M, Döhner K, Wiesneth M, Döhner H, Hofmann S. Immune responses against the mutated region of cytoplasmatic nucleophosmin 1 (NPM1) might contribute to the favorable clinical outcome of AML patients with *NPM1* mutations (*NPM1^{mut}*). *Blood* 122:1087-8, 2013
IF: 9,898
2. Graux C, Sonet A, Maertens J, Duyster J, Greiner J, Chalandon Y, Martinelli G, Hess D, Heim D, Giles FJ, Kelly KR, Gianella-Borradori A, Longerey B, Asatiani E, Rejeb N, Ottmann OG. A phase I dose-escalation study of MSC1992371A, an oral inhibitor of aurora and other kinases, in advanced hematologic malignancies. *Leuk Res* 37:1100-06, 2013
IF: 2,764
3. Babiak A, Steinhäuser M, Götz M, Herbst C, Döhner H, Greiner J. Frequent T cell responses against immunogenic targets in lung cancer patients for targeted immunotherapy. *Leuk Lymphoma* 54:1500-4, 2013
IF: 2,297
4. Bullinger L, Schlenk RF, Götz M, Botzenhardt U, Hofmann S, Russ AC, Babiak A, Zhang L, Schneider V, Döhner K, Schmitt M, Döhner H, Greiner J. PRAME induced inhibition of retinoic acid receptor signaling-mediated differentiation – an explanation for ATRA response in AML without t(15;17). *CCR* 19:2562-71, 2013
IF: 7,742
5. Heinz WJ, Egerer G, Lellek H, Boehme A, Greiner J. Posaconazole after previous antifungal therapy with voriconazole for therapy of invasive aspergillus disease, a retrospective analysis. *Mycoses* 56:304-10, 2013
IF: 2,747
6. Schneider V, Egenrieder S, Götz M, Herbst C, Greiner J, Hofmann S. Specific immune responses against epitopes derived from Aurora kinase A and B in acute myeloid leukemia. *Leukemia & Lymphoma* 54:1500-04, 2013
IF: 2,580
7. Hofmann S, Götz M, Schneider V, Guillaume P, Bunjes D, Döhner H, Wiesneth M, Greiner J. Donor lymphocyte infusion induces polyspecific CD8+ T cell responses with concurrent molecular remission in AML with *NPM1* mutation. *JCO* 31:e44-47, 2013
IF: 18,372

8. Sockel K, Bornhaeuser M, Mischak-Weissing E, Trenscher R, Wermke M, Unzicker C, Kobbe G, Finke J, Germing U, Mohr B, Greiner J, Beelen D, Thiede C, Ehninger G, Platzbecker U; on behalf of the German MDS and Cooperative Transplant Study Group (GCTSG). Lenalidomide maintenance after allogeneic HSCT seems to trigger acute graft-versus-host disease in patients with high-risk myelodysplastic syndromes or acute myeloid leukemia and del(5q): results of the LENAMAINT trial. *Haematologica* 97:e34-e35, 2012
IF: 6,424
9. Greiner J, Ono Y, Hofmann S, Schmitt A, Mehring E, Götz M, Guillaume P, Döhner K, Mytilineos J, Döhner H, Schmitt M. Mutated regions of nucleophosmin 1 (NPM1) elicit both CD4+ and CD8+ T cell responses in patients with acute myeloid leukemia (AML). *Blood* 120:1282-9, 2012
IF: 9,898
10. Faderl S, Wetzler M, Rizzieri DA, Schiller GJ, Jagasia M, Stuart R, Ganguly S, Avigan D, Craig M, Collins R, Maris M, Kovacovics T, Goldberg S, Seiter K, Hari P, Greiner J, Vey N, Recher C, Ravandi F, Wang E, Vasconcelles M, Huebner D, Kantarjian HM. Clofarabine Plus Cytarabine Compared with Cytarabine Alone in Older Patients with Relapsed or Refractory Acute Myelogenous Leukemia: Results from the Randomized, Double-Blind, Placebo-Controlled Phase 3 CLASSIC I Trial. *J Clin Oncol* 30:2492-9, 2012
IF: 18,372
11. Zhang L, Götz M, Hofmann S, Greiner J. Immunogenic targets for specific immunotherapy in multiple myeloma. *Clin Dev Immunol* 2012:820394, 2012
IF: 1,838
12. Zhang L*, Hofmann S*, Guillaume P, Schneider V, Greiner J. Most favourable PRAME epitopes. e-Letter *Blood* November 16, 2011. Accessed April 19, 2012.
http://bloodjournal.hematologylibrary.org/content/117/12/3353/reply#bloodjournal_el_2260
IF: 9,898
13. Schmitt M, Neubauer A, Greiner J, Xu X, Barth TF, Bechter K. Spreading of acute myeloid leukemia cells by trafficking along the peripheral outflow pathway of cerebrospinal fluid. *Anticancer Res* 31:2343-5, 2011
IF: 1,725
14. Reiser M, Wieland A, Plachter B, Mertens T, Greiner J, Schirmbeck R. The immunodominant CD8 T cell response to the human cytomegalovirus tegument phosphoprotein pp65(495-503) epitope critically depends on CD4 T cell help in vaccinated HLA-A*0201 transgenic mice. *J Immunol* 187:2172-80, 2011
IF: 5,788
15. Zhang L, Greiner J. Leukemia-associated antigens are immunogenic and have prognostic value in AML. *Immunotherapy* 3:697-9, 2011
IF: 1,854

16. Hofmann S, Greiner J. Adoptive immunotherapy after allogeneic hematopoietic progenitor cell transplantation: New perspectives for transfusion medicine. *Transfusion Medicine and Hemotherapy* 38: 173-182, 2011
IF: 1,164
17. Hofmann S, Babiak A, Greiner J. Immunotherapy for Myeloproliferative Neoplasms (MPN). *Curr Cancer Drug Targets* 11: 72-84, 2011
IF: 4,327
18. Schmitt A, Tonn T, Busch DH, Grigoleit GU, Einsele H, Odendahl M, Germeroth L, Ringhoffer M, Ringhoffer S, Wiesneth M, Greiner J, Michel D, Mertens T, Rojewski M, Marx M, Von Harsdorf S, Döhner H, Seifried E, Bunjes D, Schmitt M. Adoptive transfer and selective reconstitution of streptamer-selected cells leads to virus clearance in cytomegalovirus-specific CD8+ T patients after allogeneic peripheral blood stem cell transplantation. *Transfusion* 51:591-9 2011
IF: 3,217
19. Greiner J, Küfer R, Reske SN, Martin V, Döhner H, Ringhoffer M. Metronomic treatment with low-dose trofosfamide leads to a long-term remission in a patient with docetaxel-refractory advanced metastatic prostate cancer. *Case Reports in Medicine* 2010:395720, 2010
IF: not listed
20. Hofmann S, Greiner J. Immunogenic antigens as therapeutic targets against myeloid leukaemic cells. *Leuk Res* 34:850-1, 2010
IF: 2,923
21. Giannopoulos K, Dmoszynska A, Kowal M, Rolinski J, Gostick E, Price DA, Greiner J, Rojewski M, Stilgenbauer S, Döhner H, Schmitt M. Peptide vaccination elicits leukemia-associated antigen-specific cytotoxic CD8(+) T-cell responses in patients with chronic lymphocytic leukemia. *Leukemia* 24:798-805, 2010
IF: 9,561
22. Greiner J, Schmitt A, Giannopoulos K, Rojewski MT, Götz M, Funk I, Ringhoffer M, Bunjes D, Hofmann S, Ritter G, Döhner H, Schmitt M. High dose RHAMM-R3 peptide vaccination for patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS) and multiple myeloma (MM). *Haematologica* 95:1191-7, 2010
IF: 6,424
23. Fei F, Yu Y, Schmitt A, Rojewski MT, Chen B, Greiner J, Götz M, Bunjes D, Schmitt M. Effects of nilotinib on regulatory T cells: the dose matters. *Mol Cancer* 9:22, 2010
IF: 3,993

24. Ringhoffer, Rinnab L, Küfer R, **Greiner J**. Systemic therapy of metastatic renal cell carcinoma: from many options to the therapeutic strategy. [Article in German] *Urologe* 48:1308-17, 2009
IF: 0,497
Gust M, Hofer MD, Perner SR, Kim R, Chinnaiyan AM, Varambally S, Moller P, Rinnab L, Rubin MA, **Greiner J**, Schmitt M, Kuefer R, Ringhoffer M. RHAMM (CD168) is overexpressed at the protein level and may constitute an immunogenic antigen in advanced prostate cancer disease. *Neoplasia* 11: 956-63, 2009
IF: 5,946

25. Bommer M, Pauls S, **Greiner J**. Challenging complications of treatment--human herpes virus 6 encephalitis and pneumonitis in a patient undergoing autologous stem cell transplantation for relapsed Hodgkin's disease: a case report. *Virology* 6: 111, 2009
IF: 2,343

26. Guinn B*, **Greiner J***, Schmitt M, and Mills K (*contributed equally). Elevated expression of the leukaemia associated antigen SSX2IP predicts good survival in acute myeloid leukaemia patients who lack detectable cytogenetic rearrangements. *Blood* 113: 1203-4, 2009
IF: 9,898

27. **Greiner J**, Schmitt M. T cell therapy for patients targeting Leukemia-associated antigens (LAAs) in haematological malignancies and after allogeneic stem cell transplantation. *New Insights on Hematopoietic Cell Transplantation*, 2009 (Buchbeitrag)
IF: not listed

28. Schmitt A, Barth TF, Beyer E, Borchert F, Rojewski M, Chen J, Guillaume P, Gronau S, **Greiner J**, Möller P, Riechelmann H, Schmitt M. The tumor antigens RHAMM and G250/CAIX are expressed in head and neck squamous cell carcinomas and elicit specific CD8+ T cell responses. *Int J Oncol* 34: 629-39, 2009
IF: 2,399

29. Giannopoulos K, Mertens D, Buehler A, Barth TFE, Idler I, Möller P, Kröber A, **Greiner J**, Chocholska S, Dmoszynska A, Rolinski J, Döhner H, Stilgenbauer S, Schmitt M. The candidate immunotherapeutic target receptor for hyaluronic acid mediated motility (RHAMM) is associated with proliferation and shows prognostic value in B-cell chronic lymphocytic leukemia. *Leukemia* 23: 519-27, 2009
IF: 9,561

30. **Greiner J**, Guinn B, Döhner H, Bullinger L, Schmitt M. Leukemia-associated antigens (LAAs) are critical for the proliferation of acute myeloid leukemia cells. *Clin Cancer Res* 14: 1-6, 2008
IF: 7,742

31. **Greiner J**, Schmitt M. Current status of peptide vaccines for cancer immunotherapy in malignant myeloid diseases. *Memo* 1: 1-4, 2008c
IF: not listed

32. Greiner J, Schmitt M. Leukemia-Associated Antigens (LAAs) as target structures for a specific immunotherapy in Chronic myeloid leukemia (CML). *Eur J Hematol* 80: 461-468, 2008
IF: 2,614
33. Fei F, Yu Y, Schmitt A, Chen B, Rojewski M, Ringhoffer M, von Harsdorf S, Greiner J, Götz M, Guillaume P, Döhner H, Bunjes D, Schmitt M. Dasatinib exerts an immunosuppressive effect on CD8⁺ T cells specific for viral and leukemia-antigens. *Exp Hematol* 36: 1297-1308, 2008
IF: 2,905
34. Chen J, Schmitt A, Chen B, Rojewski M, Rübeler V, Fei F, Yu Y, Yu X, Ringhoffer M, von Harsdorf S, Greiner J, Götz M, Guillaume P, Döhner H, Bunjes D, Schmitt M. Nilotinib hampers the proliferation and function of CD8⁺ T lymphocytes through inhibition of T cell receptor signaling. *J Cell Mol Med* 12: 2107-2118, 2008
IF: 4,125
35. Schmitt M, Schmitt A, Rojewski MT, Chen J, Giannopoulos K, Fei F, Yu Y, Götz M, Heyduk M, Ritter G, Speiser D, Gnjatic S, Guillaume P, Ringhoffer M, Schlenk RF, Liebisch P, Bunjes D, Shiku H, Döhner H, Greiner J. RHAMM-R3 peptide vaccination in patients with acute myeloid leukemia, myelodysplastic syndrome and multiple myeloma elicits immunological and clinical responses. *Blood* 111: 1357-1365, 2008
IF: 9,898
36. Guinn B, Bullinger L, Thomas NS, Mills KI, Greiner J. SSX2IP expression in acute myeloid leukaemia patients: an association with mitotic spindle failure and t(8;21), and cell cycle and t(15;17). *Br J Haematol* 140: 250-1, 2008
IF: 4,941
37. Schmitt A, Li Li, Giannopoulos K, Greiner J, Reinhardt P, Wiesneth M, Schmitt M. Quantitative expression of Toll-like receptor-2, -4 and -9 in dendritic cells generated from blasts of patients with acute myeloid leukemia. *Transfusion* 48: 861-870, 2008
IF: 3,217
38. Greiner J, Schmitt M. Cancer testis/germline antigens (CT/CG-antigens) in leukemias. *Leuk Res* 31: 1-3, 2007
IF: 2,923
39. Guinn B, Mills KI, Czepulkowski B, Schmitt M, Greiner J. Leukaemia associated antigens and their dual role as biomarkers and therapeutical targets for acute myeloid leukaemia. *Biomarker Insights* 2: 1-11, 2007
IF: not listed

40. Metaxas Y, Spyridonidis A, Bertz H, Finke J, Greiner J. Donor derived mucosal epithelial cells after human hematopoietic cell transplantation are not derived from the CD34 positive fraction of the graft. *Leukemia* 21: 2214-16, 2007
IF: 9,561
41. Wiehe J, Ponsaerts P, Rojewski M, Homann J, Greiner J, Kronawitter D, Schrezenmeier H, Hombach V, Wiesneth M, Zimmermann O, Torzewski J. mRNA-mediated gene delivery into human progenitor cells promotes highly efficient protein expression. *J Cell Mol Med* 11: 521-30, 2007
IF: 4,125
42. Ringhoffer M, Harsdorf SV, Schmitt M, Wiesneth M, Zenz T, Stilgenbauer S, Greiner J, Dohner K, Marx M, Dohner H, Bunjes D. Reduced-intensity conditioning followed by T-cell depleted allogeneic stem cell transplantation for patients with chronic myeloid leukaemia and minimal residual disease at the time of transplant: high risk of molecular relapse. *Br J Haematol* 136: 127-130, 2007
IF: 4,941
43. Chen J, Schmitt A, Chen B, Rojewski M, Ringhoffer M, von Harsdorf S, Greiner J, Guillaume P, Dohner H, Bunjes D, Schmitt M. Imatinib impairs CD8+ T lymphocytes specifically directed against the leukemia-associated antigen RHAMM/CD168 in vitro. *Cancer Immunol Immunother* 56: 849-61, 2007
IF: 3,701
44. Greiner J, Döhner H, Schmitt M. Cancer vaccines for patients with acute myeloid leukemia--definition of leukemia-associated antigens and current clinical protocols targeting these antigens. *Haematologica* 91: 1653-61, 2006
IF: 6,424
45. Greiner J*, Schmitt M*, Li Li, Giannopoulos K, Bösch K, Schmitt A, Döhner K, Schlenk RF, Pollack JR, Döhner H, Bullinger L (*contributed equally). Expression of tumor-associated antigens in acute myeloid leukemia: implications for specific immunotherapeutic approaches. *Blood* 108: 4109-17, 2006
IF: 9.898
46. Schmitt M, Li Li, Giannopoulos K, Chen J, Brunner C, Barth T, Schmitt A, Wiesneth M, Döhner K, Döhner H, Greiner J. Chronic myeloid leukemia (CML) cells express tumor associated antigens eliciting specific CD8+ T cell responses and are lacking costimulatory molecules. *Exp Heamatol* 34: 1709-19, 2006
IF: 2,905
47. Giannopoulos K, Li L, Bojarska-Junak A, Rolinski J, Dmoszynska A, Hus I, Greiner J, Renner C, Döhner H, Schmitt M. Expression of RHAMM/CD168 and other tumor associated antigens in patients with B-cell chronic lymphocytic leukemia. *Int J Oncol* 29: 95-103, 2006
IF: 2,399

48. Wiehe J, Niesler C, Torzewski J, Zimmermann O, Wiesneth M, Schmitt M, Schwarz K, Döhner H, Hombach V, Greiner J. Efficient transient genetic labeling of human CD34+ progenitor cells for in vivo application. *Regenerative Med* 1: 223-234, 2006
IF: 3,718
49. Li L, Giannopoulos K, Reinhardt P, Tabarkiewicz J, Schmitt A, Greiner J, Rolinski J, Hus I, Dmoszyska A, Wiesneth M, Schmitt M. Immunotherapy for patients with acute myeloid leukemia using autologous dendritic cells generated from leukemic blasts. *Int J Oncol* 28: 855-61, 2006
IF: 2,399
50. Wiehe J, Zimmermann O, Greiner J, Homann J, Wiesneth M, Hombach V, Torzewski J. Labeling of adult stem cells for in vivo application in the human heart. *Histol Histopathol* 20:901-6, 2005
IF: 2,480
51. Schmitt, M, Greiner J. Definition of Immunogenic antigens in chronic myeloid leukemia (CML) towards the development of cancer vaccines. *Leuk Res* 29: 1367-9, 2005
IF: 2,923
52. Hus I, Roliński J, Tabarkiewicz J, Wojas K, Bojarska-Junak A, Greiner J, Giannopoulos K, Dmoszyńska A, Schmitt M. Allogeneic dendritic cells pulsed with tumor lysates or apoptotic bodies as immunotherapy for patients with early stage B-cell chronic lymphocytic leukemia (B-CLL). *Leukemia* 19: 1621-7, 2005
IF: 9,561
53. Greiner J, Li L, Ringhoffer M, Barth T, Wiesneth M, Döhner H, Schmitt M. Identification and characterization of epitopes of the receptor for hyaluronic acid mediated motility (RHAMM/CD168) recognized by CD8 positive T cells of HLA-A2 positive patients with acute myeloid leukemia. *Blood* 106: 938-45, 2005
IF: 9,898
54. Li Li, Reinhardt P, Schmitt A, Barth TFE, Greiner J, Ringhoffer M, Döhner H, Wiesneth M, Schmitt M. Dendritic cells generated from acute myeloid leukemia (AML) blasts maintain the expression of immunogenic leukemia associated antigens. *Cancer Immunol Immunother* 54: 685-93, 2005
IF: 3,701
55. Greiner J, Ringhoffer M, Taniguchi M, Schmitt A, Shiku H, Döhner H, Schmitt M. mRNA expression for leukemia-associated antigens in patients with acute myeloid leukemia for the development of specific immunotherapies. *Int J Cancer* 108: 704-11, 2004
IF: 5,444
56. Ringhoffer M, Müller CR, Schenk A, Kirsche H, Schmitt M, Greiner J, Döhner H, Gschwend JE. Simultaneous expression of T cell activating antigens in renal cell carcinoma: Implications for specific immunotherapy. *J Urol* 171: 2456-60, 2004
IF: 3,746

57. Greiner J, Wiehe J, Wiesneth M, Zwaka TP, Prill T, Schwarz K, Bienek-Ziolkowski M, Schmitt M, Döhner H, Hombach V, Torzewski J. Transient genetic labeling of human CD34 positive hematopoietic stem cells using nucleofection. *Transfus Med Hemother* 31: 136-41, 2004
IF: 1,164
58. Greiner J, Ringhoffer M, Taniguchi M, Hauser T, Schmitt A, Döhner H, Schmitt M. Characterization of several leukemia-associated antigens inducing humoral immune responses in acute and chronic myeloid leukemia (AML/CML). *Int J Cancer* 106: 224-31, 2003
IF: 5,444
59. Li L, Schmitt A, Reinhardt P, Greiner J, Ringhoffer M, Vaida B, Brommer M, Vollmer M, Wiesneth M, Döhner H, Schmitt M. Reconstitution of CD40 and CD80 in dendritic cells generated from blasts of patients with acute myeloid leukemia. *Cancer Immun* 3: 8, 2003
IF: not listed
60. Vollmer M, Li L, Schmitt A, Greiner J, Reinhardt P, Ringhoffer M, Wiesneth M, Döhner H, and Schmitt M. Expression of human leucocyte antigens and costimulatory molecules on blasts of patients with acute myeloid leukaemia. *Br J Haematol* 120: 1000-8, 2003
IF: 4,941
61. Greiner J, Ringhoffer M, Taniguchi M, Schmitt A, Kirchner D, Krähn G, Heilmann V, Gschwend J, Bergmann L, Döhner H, and Schmitt M. Receptor for hyaluronan acid-mediated motility (RHAMM) is a new immunogenic leukemia-associated antigen in acute and chronic myeloid leukemia. *Exp Hematol* 30: 1029-35, 2002
IF: 2,905
62. Greiner J, Ringhoffer M, Simikopinko O, Szmargowska A, Huebsch S, Maurer U, Bergmann L, Schmitt M. Simultaneous expression of different immunogenic antigens in acute myeloid leukemia. *Exp Hematol* 28: 1413-22, 2000
IF: 2,905

Impact Factor as a First/Last Author: 193

Overall Impact Factor: 308

Kongressbeiträge

1. Schneider V, Bullinger L, Zhang L, Rojewski M, Wiesneth M, Hofmann S, Götz M, Schrezenmeier H, Botzenhardt U, Barth TFE, Döhner K, Döhner H, Greiner J. Analysis of leukemic stem cell population comparing *NPM1^{wt}* and *NPM1^{mut}* AML patients and potential therapeutic targets. *Onkologie* 36 (suppl 7) V702 [DGHO] 2013
2. Hofmann S, Schneider V, Schmitt M, Götz M, Döhner K, Wiesneth M, Döhner H, Greiner J. Immune responses against the mutated region of cyto-plasmatic nucleophosmin 1 (NPM1) might contribute to the favorable clinical outcome of AML patients with NPM1 mutations (NPM1mut). *Onkologie* 36 (suppl 7) V684 [DGHO] 2013
3. Bullinger L, Zhang L, Rojewski M, Wiesneth M, Hofmann S, Götz M, Schrezenmeier H, Botzenhardt U, Barth TFE, Döhner K, Döhner H, Greiner J. Analysis Of Leukemic Stem Cell Population Comparing *NPM1^{wt}* and *NPM1^{mut}* AML Patients and Potential Therapeutic Targets. *Blood (ASH Annual Meeting Abstracts)* 122: 2624, 2013
4. Schneider V, Zhang L, Bullinger L, Rojewski M, Hofmann S, Wiesneth M, Schrezenmeier H, Götz M, Botzenhardt U, Barth TFE, Döhner K, Döhner H, Greiner J. Characterization of leukemic stem cells in patients with *NPM1^{mut}* and *NPM1^{wt}* AML and potential therapeutic targets. . *Blood (ASH Annual Meeting Abstracts)* 122: , 2013
5. Hofmann S, Schneider V, Bullinger L, Ono Y, Schmitt A, Zhang L, Götz M, Döhner K, Mytilineos J, Wiesneth M, Döhner H, Schmitt M, Greiner J. Mutated Nucleophosmin 1 (NPM1) Is an Immunogenic Target and Patients with *NPM1^{mut}* Acute Myeloid Leukemia (AML) Showed High Expression of Different Leukemia-Associated Antigens (LAAs). *Blood (ASH Annual Meeting Abstracts)* 120: 3592, 2012
6. Greiner J, Ono Y, Hofmann S, Schneider V, Schmitt A, Zhang L, Mehring E, Götz M, Döhner K, Mytilineos J, Wiesneth M, Döhner H, Schmitt M. Effect of epitopes derived from the mutated region of cytoplasmatic nucleophosmine 1 (NPM1) on CD4+ and CD8+ T-cell responses in patients with acute myeloid leukemia. *Proc Americ Soc Clin Oncol, (ASCO Meeting Abstracts)* 6576: 2012
7. Greiner J, Hofmann S, Schneider V, Ono Y, Schmitt A, Zhang L, Mehring E, Götz M, Döhner K, Mytilineos J, Wiesneth M, Döhner H, Schmitt M. Mutated regions of nucleophosmin 1 (NPM1) elicit both CD4+ and CD8+ T cell responses in patients with acute myeloid leukemia (AML). *Onkologie* 35 (suppl 6) P198 [DGHO] 2012
8. Greiner J. Immunogenic target structures for an adoptive T cell transfer after allogeneic stem cell transplantation for patient with acute leukemia. *Onkologie* 35 (suppl 6) V267 [DGHO] 2012
9. Schneider V, Bullinger L, Zhang L, Rojewski M, Hofmann S, Götz M, Landshammer A, Botzenhardt U, Barth TFE, Döhner H, Greiner J. Efficient enrichment of CD34+ cells NPM1 mutated AML patients. *Onkologie* 35 (suppl 6) V358 [DGHO] 2012

10. Hofmann S, Götz M, Herbst C, Schneider V, Weißschuh M, Bunjes D, Döhner H, Wiesneth M, Greiner J. Immune responses against several leukaemia-associated-antigens (LAAs) in the course of allogeneic hematopoietic stem cell transplantation (allo-HSCT) and donor lymphocyte infusion (DLI) in patients with different haematological diseases. *Onkologie* 35 (suppl 6) P436 [DGHO] 2012
11. Hofmann S, Götz M, Herbst C, Schneider V, Zhang L, Bunjes D, Döhner H, Wiesneth M, Greiner J. Donor lymphocyte infusion induces polyspecific CD8+ T cell responses with concurrent molecular remission in AML with NPM1 mutation. CIMT, 10th Annual Meeting, Mainz, 2012
12. Greiner J, Ono Y, Hofmann S, Schneider V, Schmitt A, Zhang L, Mehring E, Götz M, Döhner K, Mytilineos J, Wiesneth M, Döhner H, Schmitt M. Epitopes derived from the mutated region of Nucleophosmine 1 (NPM1) induce both CD4+ and CD8+ T Cell responses. CIMT, 10th Annual Meeting, Mainz, 2012
13. Greiner J, Ono Y, Hofmann S, Schneider V, Schmitt A, Zhang L, Mehring E, Götz M, Döhner K, Mytilineos, Wiesneth M, Döhner H, Schmitt M. The Mutated Region of Cytoplasmic Nucleophosmine 1 (NPM1) Elicits Both CD4+ and CD8+ T Cell Responses. *Blood (ASH Annual Meeting Abstracts)* 118: 2569, 2011
14. Sockel K, Greiner J, Trenschele R, Unzicker C, Kobbe G, Finke J, Germing U, Mohr B, Beelen D, Ehninger G, Bornhaeuser M, Platzbecker U. Early Lenalidomide Maintenance to Prevent Relapse of High-Risk MDS and AML Patients with Del(5q) Following Allogeneic HCT - Results of the "LENAMAINT" Trial. *Blood (ASH Annual Meeting Abstracts)* 118: 3060, 2011
15. Zhang L, Hofmann S, Bullinger L, Götz M, Wiesneth M, Rojewski M, Döhner H, Greiner J, Schneider V. Efficiency of Leukemic Stem Cell Separation From Patients with Acute Myeloid Leukemia. *Blood (ASH Annual Meeting Abstracts)* 118: 4997, 2011
16. Hofmann S, Götz M, Herbst C, Schneider V, Zhang L, Bunjes D, Döhner H, Wiesneth M, Greiner J. Preemptive Donor Lymphocyte Infusion Induces Polyspecific T-Cell Responses in a Patient with AML with NPM1 Mutation. *Blood (ASH Annual Meeting Abstracts)* 118: 4311, 2011
17. Casalegno-Garduño R, Meier C, Mani J, Borchert K, Hilgendorf I, Gross Y, Filipowska A, Koczan D, Spitschak A, Linnebacher M, Schmitt A, Greiner J, Freund M, Pützer BM, Schmitt M. Expression of RHAMM and WT1 As Well As T Cell Responses to These Antigens Before and After Allogeneic Stem Cell Transplantation in Patients with Leukemia. *Blood (ASH Annual Meeting Abstracts)* 118: 4315, 2011
18. Hofmann S, Bullinger L, Schlenk RF, Götz M, Botzenhardt U, Babiak A, Zhang L, Schneider V, Döhner K, Schmitt M, Döhner H, Greiner J. Preferentially expressed antigen of melanoma (PRAME) is a prognostic marker, predictive for ATRA treatment response and an immunotarget with two favourable epitopes.
20. CIMT, 9th Annual Meeting, Mainz, 2011

21. Babiak, A, Conzelmann J, Steinhauser M, Hofmann S, Schneider V, Götz M, Zhang L, Döhner H, Greiner J. In patients with metastatic lung cancer several novel and known immunogenic tumor-associated antigens (TAA) induce specific T-cell responses and are therefore candidates for targeted immunotherapies. *Onkologie* 34 (suppl 6) P526 [DGHO] 2011
22. Greiner J, Hofmann S, Schlenk RF, Götz M, Botzenhardt U, Zhang L, Schneider V, Döhner K, Schmitt M, Döhner H, Bullinger L. PRAME is a prognostic immunogenic target in AML harboring two dominant T-cell epitopes and playing a critical role in leukemic cell proliferation and differentiation. *Onkologie* 34 (suppl 6) V655 [DGHO] 2011
23. Hofmann S, Götz M, Herbst C, Zhang L, Schneider V, Bunjes D, Wiesneth M, Döhner H, Greiner J. Simultaneous immune responses against several leukaemia-associated-antigens (LAAs) after donor lymphocyte infusion (DLI) in a patient with acute myeloid leukaemia (AML). *Onkologie* 34 (suppl 6) P913 [DGHO] 2011
24. Zhang L, Hofmann S, Götz M, Herbst C, Döhner H, Greiner J, Schneider V. Efficient methods for leukemic stem cell separation. *Onkologie* 34 (suppl 6) P872 [DGHO] 2011
25. Babiak AM, Steinhauser M, Hofmann S, Conzelmann J, Schneider V, Götz M, Zhang L, Döhner H, Greiner J. Implications of specific T-cell responses by different novel and known immunogenic tumor-associated antigens (TAA) in patients with metastatic lung cancer. *Proc Americ Soc Clin Oncol, (ASCO Meeting Abstracts)* 10619: 2011
26. Greiner J, Hofmann S, Giannopoulos K, Rojewski M, Babiak A, Bunjes D, Döhner H, Schmitt A, Schmitt M. Serological profiling of patients with different hematological malignancies before and after RHAMM-R3 peptide vaccination and correlation to specific T cell responses and clinical findings. *Onkologie* 33 (suppl 4) V331 [DGHO] 2010
27. Babiak A., Steinhauser M., Hofmann S., Döhner H., Greiner J. Several tumor-associated antigens induce specific T cell responses in patients with metastatic lung cancer in a high frequency and are therefore immunogenic targets for (polyvalent) vaccination strategies. *Onkologie* 33 (suppl 4) P526 [DGHO] 2010
28. Babiak AM, Steinhauser M, Döhner H, Greiner J. Effect of tumor-associated antigens on specific T-cell responses in patients with metastatic lung cancer and potential use as immunogenic targets for a (polyvalent) vaccination strategy. *Proc Americ Soc Clin Oncol, (ASCO Meeting Abstracts)* e13064: 2010
29. Giannopoulos K, Dmoszynska A, Rolinski J, Greiner J, Stilgenbauer S, Schmitt M. Identification of RHAMM-derived CD8+ restricted, heteroclitical, cryptic epitope R9Y as a promising target for immunotherapy of chronic lymphocytic leukemia. *Haematologica* 95: 0740, [EHA] 2010

30. Giannopoulos K, Dmoszynska A, Rolinski J, Greiner J, Stilgenbauer S, Schmitt M Identification of RHAMM-Derived CD8⁺ Restricted, Heteroclitical, Cryptic Epitope R9Y as a Promising Target for Immunotherapy of Chronic Lymphocytic Leukemia. Blood (ASH Annual Meeting Abstracts) 114: 3034, 2009
31. Greiner J, Hofmann S, Giannopoulos K, Rojewski M, Babiak A, Bunjes D, Döhner H, Schmitt A, Schmitt M. Co-Existing serological immune responses against RHAMM might be a prerequisite for strong cellular immune responses of CD8-positive T cells in RHAMM-R3 peptide vaccination for patients with different hematological malignancies. Blood (ASH Annual Meeting Abstracts) 114: 3671, 2009
32. Giannopoulos K, Greiner J, Price DA, Gostick E, Kowal M, Dmoszynska A, Rolinski J, Rojewski M, Stilgenbauer S, Döhner H, Schmitt M. Peptide vaccination effectively mounts cytotoxic T-cell responses with potential clinical relevance in patients with chronic lymphocytic leukemia. Onkologie 32 (suppl 4) V331 [DGHO] 2009
33. Greiner J, Schmitt M, Schmitt A, Götz M, Fickler J, Döhner H, Bullinger L. PRAME mRNA transfection into AML cell lines induces ATRA resistance and an inhibition of cell differentiation. Onkologie 32 (suppl 4) P429 [DGHO] 2009
34. Greiner J, Schmitt A, Giannopoulos K, Hofmann S, Rojewski M, Götz M, Guillaume P, Ringhoffer M, Bommer M, Funk I, Döhner H, Schmitt M. Higher rates of immunological responses in patients with haematological malignancies received 300µg RHAMM R3 peptide in contrast to high-dose peptide vaccination. Onkologie 32 (suppl 4) P479 [DGHO] 2009
35. Schmitt M, Bechter K, Barth TFE, Greiner J, Neubauer A. Unusual metastasis of acute myeloid leukemia cells by trafficking along the peripheral efflux pathway of cerebrospinal fluid. Onkologie 32 (suppl 4) P696 [DGHO] 2009
36. Giannopoulos K, Dmoszynska A, Kowal M, Rolinski J, Gostick E, Price DA, Greiner J, Rojewski M, Stilgenbauer S, Döhner H, Schmitt M. Peptide vaccination elicits leukemia-associated antigen-specific cytotoxic CD8⁺ T-cell responses with potential clinical relevance in patients with chronic lymphocytic leukemia. Haematologica 94: 0066, [EHA] 2009
37. Greiner J, Schmitt A, Giannopoulos K, Rojewski M, Götz M, Ritter G, Gnjatic S, Guillaume P, Ringhoffer M, Bommer M, Schlenk RF, Bunjes D, Döhner H, Schmitt M. High-dose RHAMM-R3 peptide vaccination for patients with acute myeloid leukemia, myelodysplastic syndrome and multiple myeloma. Haematologica 94: 0068, [EHA] 2009
38. Greiner J, Guinn BA, Döhner H, Mills KI, Bullinger L. Survivin expression impacts on survival in acute myeloid leukemia patients. Haematologica 94: 0829, [EHA] 2009

39. Fei F, Yu Y, Schmitt A, Chen J, Chen B, Rojewski M, Greiner J, Götz M, Guillaume P, Döhner H, Bunjes D, Schmitt M. Dasatinib, nilotinib and imatinib exert immunosuppression on leukaemia and viral antigen specific CD8+ T-lymphocytes and CD4+CD25+FoxP3+ regulatory T-cells through downregulation of the NF-B pathway. BMT (EBMT Annual Meeting Abstracts) 41:P777, 2008
40. Sonet A, Graux C, Maertens J, Hartog CM, Duyster J, Götz K, Greiner J, Hütter ML, Gratwohl A, Heim D, Hess D, Chalandon Y, Gianella-Borradori A, Rejeb N, Ottmann O. Phase I, Dose-Escalation Study of 2 Dosing Regimens of AS703569, An Inhibitor of Aurora and Other Kinases, Administered Orally in Patients with Advanced Hematological Malignancies. Blood (ASH Annual Meeting Abstracts) 112: 2963, 2008
41. Greiner J, Schmitt A, Giannopoulos K, Funk I, Heyduk M, Rojewski M, Chen J, Götz M, Bommer M, Ritter G, Guillaume P, Dmoszynska A, Döhner H, Schmitt M. High-Dose RHAMM-R3 Peptide Peptide Vaccination for Patients with Vaccination for Patients with Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Multiple Myeloma (MM) and Chronic Lymphocytic Leukemia (CLL). Blood (ASH Annual Meeting Abstracts) 112: 2911, 2008
42. Giannopoulos K, Kowal M, Dmoszynska A, Rolinski J, Mazurek K, Greiner J, Rojewski M, Stilgenbauer S, Döhner H, Schmitt M. Peptide Vaccination Induces Dynamic Changes in CD4+ and CD8+ T Cell Subsets: Report on the First Peptide Vaccination Trial in Patients with Chronic Lymphocytic Leukemia (CLL). Blood (ASH Annual Meeting Abstracts) 112: 3159, 2008
43. Greiner J, Bullinger L, Giannopoulos K, Schmitt A, Goetz M, Kienle L, Döhner H, Schmitt M. The Leukemia-Associated Antigen PRAME Is Overexpressed in Myeloid Leukemias and Inhibits Cell Differentiation by Blocking the Receptor for Retinoic Acid (RAR)-Signaling in Vitro and Is Therefore a Interesting Candidate for Targeted Immunotherapies. Blood (ASH Annual Meeting Abstracts) 112: 1524, 2008
44. Giannopoulos K, Mertens D, Kowal M, Buehler A, Barth TFE, Idler I, Greiner J, Własiuk P, Chocholska S, Dmoszyńska A, Roliński J, Döhner H, Stilgenbauer S, Schmitt M. The candidate immunotherapeutical target *receptor for hyaluronic acid mediated motility* (RHAMM) is associated with proliferation and shows prognostic value in B-cell chronic lymphocytic leukemia. Onkologie 31, (Suppl. 4), P221, [DGHO] 2008
45. Schmitt M, Schmitt A, Giannopoulos K, Chen J, Li L, Liebisch P, Ringhoffer M, Guillaume P, Ritter G, Rojewski M, Gnjjatic S, Döhner H, Greiner J. RHAMM/CD168-R3 peptide vaccination of patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), multiple myeloma (MM) and chronic lymphatic leukemia (CLL) elicits immunological and clinical responses. Onkologie 31, (Suppl. 4), P544 [DGHO] 2008
46. Greiner J, Bullinger L, Guinn B, Döhner H, Schmitt M. Leukemia-associated antigens have a dual role: LAAs are critical for the proliferation of acute myeloid cells but also induce specific T cell responses and are therefore appropriate candidates for immunotherapeutic approaches. Onkologie 31, (Suppl. 4): P159, [DGHO] 2008

47. Greiner J, Bullinger L, Giannopoulos K, Schmitt A, Döhner H, Schmitt M. The immunogenic antigen PRAME is overexpressed in myeloid leukemias and inhibits cell differentiation by blocking the receptor for retinoic acid (RAR)-signaling in vitro and is therefore a candidate for targeted immunotherapies. *Onkologie* 31, (Suppl. 4): P158, [DGHO] 2008
48. Giannopoulos K, Buehler A, Mertens D, Barth TFE, Idler I, Kroeber A, Greiner J, A Dmoszynska, Rolinski J, Doehner H, Stilgenbauer S, Schmitt M. The receptor for hyaluronic acid mediated motility (RHAMM): characterization of an immunotherapeutical target which is associated with proliferation and shows prognostic value in B-cell chronic lymphocytic leukaemia (B-CLL) patients. *Haematologica* 93: 0068, [EHA] 2008
49. Greiner J, Bullinger L, Chen J, Giannopoulos K, Schmitt A, Pollak J, Döhner H, Schmitt M. PRAME inhibits cell differentiation by blocking the receptor for retinoic acid-signalling in vitro and induces at high frequency specific T cell responses in AML patients. *Onkologie* 30 (suppl 3): 122, [DGHO] 2007
50. Metaxas Y, Spyridonidis A, Bertz H, Schmitt M, Bunjes D, Finke J, Greiner J. Donor-derived mucosal epithelial cells after human haematopoietic cell transplantation are not derived from the CD 34 positive fraction of the graft. *Onkologie* 30 (suppl 3): 136, [DGHO] 2007
51. Greiner J, Wiesneth M, Schmitt M, Ponsaerts P, Rojewski M, Schrezenmeier H, Hombach V, Döhner H, Torzewski J, Wiehe J. mRNA transfection with nucleofection is an efficient tool to transiently manipulate leukaemic cells, normal CD34 positive haematopoietic progenitor cells and mesenchymal stem cells. *Onkologie* 30 (suppl 3): 208, [DGHO] 2007
52. Greiner J, Schmitt A, Giannopoulos K, Chen J, Goetz M, Rojewski M, Ritter G, Gnjatic S, Guillaume P, Ringhoffer M, Bommer M, Schlenk R F, Liebisch P, Bunjes D, Shiku H, Dohner H, Schmitt M. Immunological and clinical responses in patients with Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Multiple Myeloma (MM) and Chronic Lymphocytic Leukemia (CLL) after RHAMM-R3 peptide vaccination. *Blood (ASH Annual Meeting Abstracts)* 110: 1806, 2007
53. Giannopoulos, Buhler A, Chen J, Kroeber A, Kowal M, Dmoszynska J R, Greiner J, Dohner H, Stilgenbauer S, Schmitt M. The Receptor for Hyaluronic Acid Mediated Motility (RHAMM): Characterization as an Immunotherapeutical target in Chronic Lymphocytic Leukemia (CLL) and first results of RHAMM-derived peptide vaccination. *Blood (ASH Annual Meeting Abstracts)* 110: 2051, 2007
54. Fei F, Yu Y, Schmitt A, Chen J, Chen B, Rojewski M, Ringhoffer M, von Harsdorf S, Greiner J, Goetz M, Guillaume P, Dohner H, Bunjes D, Schmitt M. Tyrosine Kinase inhibitors Dasatinib, Nilotinib and Imatinib have an impact on both CD8+ T lymphocytes and CD4+CD25+FOXP3+ regulatory T cells by downregulation of the NF- κ B pathway. *Blood (ASH Annual Meeting Abstracts)* 110: 2368, 2007
55. Ringhoffer M, Hofer M, Varambally S, Chinnaiyan A, Rubin M, Schmitt M, Greiner J, Kuefer R. RHAMM (CD168) is overexpressed on the protein level and may serve as an immunogenic antigen in advanced prostate cancer disease. *Proc Americ Soc Clin Oncol, (ASCO Meeting Abstracts)* 5129: 2007

56. Schmitt M, Schmitt A, Giannopoulos K, Li L, Liebisch P, Chen J, Ringhoffer M, Guillaume P, Ritter G, Rojewski M, Gnjatic S, Döhner H, Greiner J. RHAMM/CD168-R3 peptide vaccination of patients with haematological malignancies elicits immunological and clinical responses. BMT (EBMT Annual Meeting Abstracts) 39: O402, 2007
57. Greiner J, Torzewski J, Ponsaerts P, Rojewski M, Kronawitter D, Schrezenmeier H, Hombach V, Döhner H, Schmitt M, Wiesneth M, Zimmermann O, Wiehe JM. Highly efficient mRNA- and cDNA-based transient gene delivery into human progenitor cells. BMT (EBMT Annual Meeting Abstracts) 39: P847, 2007
58. J. Greiner, J. Torzewski, P. Ponsaerts, M. Rojewski, D. Kronawitter, H. Schrezenmeier, V. Hombach, H. Döhner, M. Schmitt, M. Wiesneth, O. Zimmermann, J. M. Wiehe Genetic labeling of human CD34-positive hematopoietic progenitor cells and mesenchymal stem cells by highly efficient mRNA-based gene transfer. Haematologica 92: 0189, [EHA] 2007
59. J. Greiner, Schmitt A, Giannopoulos K, Chen J, Liebisch P, Ringhoffer M, Guillaume P, Ritter G, Bommer M, Rojewski M, Gnjatic S, Döhner H, Schmitt M. RHAMM/CD168-R3 peptide vaccination of patients with acute myeloid leukemia, myelodysplastic syndrome, multiple myeloma and chronic lymphatic leukemia elicits immunological and clinical responses. Haematologica 92: 0417, [EHA] 2007
60. Giannopoulos K, Hus I, Li L, Bojarska-Junak A, Greiner J, Rolinski J, Dmoszynska A, Döhner H, Schmitt M. RHAMM/CD168 might represent potential target for immunotherapy of patients with B-cell chronic lymphocytic leukemia. CIMT, 4th Annual Meeting, P30, 2006
61. Greiner J, Schmitt A, Giannopoulos K, Li L, Liebisch P, Wendl C, Chen J, Ringhoffer M, Guillaume P, Ritter G, Döhner H, Schmitt M. RHAMM/CD168-R3 peptide vaccination of patients with hematological malignancies results in immunological and clinical responses. CIMT, 4th Annual Meeting, P57, 2006
62. Greiner J, Schmitt M, Li L, Giannopoulos K, Bösch K, Döhner K, Chen J, Schmitt A, Schlenk R, Pollak J, Döhner H, Bullinger L. Tumor-associated antigens in acute myeloid leukemia – expression, specific T cell responses and correlation with survival. Onkologie 29 (Suppl. 3): V408, [DGHO] 2006
63. Greiner J, Schmitt A, Giannopoulos K, Li L, Liebisch P, Wendl C, Chen J, Ringhoffer M, Guillaume P, Ritter G, Döhner H, Schmitt M. RHAMM/CD168-R3 peptide vaccination of HLA-A2-positive patients with acute myeloid leukaemia, myelodysplastic syndrome and multiple myeloma elicits positive immunological and clinical responses. Onkologie 29 (Suppl. 3): V412, [DGHO] 2006
64. Chen J, Schmitt A, Chen B, Ringhoffer M, von Harsdorf S, Greiner J, Guillaume P, Döhner H, Bunjes D, Schmitt M. Imatinib impairs the function of both CD4+ T regulatory cells and CD8+ T lymphocytes specifically directed against the leukaemia associated antigen RHAMM/CD168. Onkologie 29 (Suppl. 3): P545, [DGHO] 2006
65. Schmitt M, Greiner J, Li L, Giannopoulos K, Bösch K, Döhner K, Schlenk R, Pollak J, Döhner H, Bullinger L. Tumor-associated antigens in acute myeloid leukemia and their correlation with survival. Haematologica 91: 0109, [EHA] 2006

66. Schmitt M, Greiner J, Li L, Chen J, Giannopoulos K, Brunner C, Döhner K, Döhner H, Greiner J. Chronic myeloid leukemia cells express tumor-associated antigens eliciting specific CD8+ T cell responses and are lacking costimulatory molecules. *Haematologica* 91: 0144, [EHA] 2006
67. Chen J, Schmitt A, Chen B, Ringhoffer M, von Harsdorf S, Greiner J, Döhner H, Bunjes D, Schmitt M. Imatinib impairs proliferation and function of CD8+ T lymphocytes specifically directed against the leukaemia-associated antigen RHAMM/CD168. *Haematologica* 91: 0364, [EHA] 2006
68. Greiner J, Schmitt A, Giannopoulos K, Li L, Liebisch P, Wendl C, Chen J, Ringhoffer M, Guillaume P, Ritter G, Döhner H, Schmitt M. RHAMM/CD168-R3 peptide vaccination of HLA-A2-positive patients with acute myeloid leukaemia, myelodysplastic syndrome and multiple myeloma elicits immunological and clinical responses. *Haematologica* 91 (Suppl. 1): 0481, [EHA] 2006
69. Finashutina Y, Schmitt M, Greiner J, Misyurin A. Humoral immune response against the PRAME antigen in patients with myeloid leukemias. *Haematologica* 91: 1364, [EHA] 2006
70. Greiner J, Schmitt M, Li L, Giannopoulos K, Bösch K, Döhner K, Schmitt A, Schlenk RF, Pollack JR, Döhner H, Bullinger L. Expression of Tumor-Associated Antigens (TAAs) in Acute Myeloid Leukemia (AML) correlated with specific T cell responses and survival. *Blood (ASH Annual Meeting Abstracts)* 108: 414, 2006
71. Schmitt M, Schmitt A, Giannopoulos K, Li L, Liebisch P, Chen J, Ringhoffer M, Guillaume P, Ritter G, Rojewski M, Gnjatic S, Döhner H, Greiner J. RHAMM/CD168-R3 Peptide Vaccination of patients with Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS) and Multiple Myeloma (MM) elicits immunological and clinical responses. *Blood (ASH Annual Meeting Abstracts)* 108: 409, 2006
72. Chen J, Schmitt A, Chen B, Rojewski M, Greiner J, Guillaume P, Döhner H, Bunjes D, Schmitt M. Imatinib inhibits both CD4+ T Regulatory Cells and CD8+ T Lymphocytes specifically directed against the Leukemia-Associated Antigen RHAMM/CD168. *Blood (ASH Annual Meeting Abstracts)* 108: 2201, 2006
73. Greiner J, Torzewski J, Ponsaerts P, Rojewski M, Kronawitter D, Schrezenmeier H, Hombach V, Döhner H, Schmitt M, Wiesneth M, Zimmermann O, Wiehe J. Highly efficient mRNA- and cDNA-based transient gene delivery into human progenitor cells. *Blood (ASH Annual Meeting Abstracts)* 108: 5471, 2006
74. Ringhoffer M, Harsdorf v S, Schmitt M, Wiesneth M, Greiner J, Zenz T, Stilgenbauer S, Döhner H, Bunjes D. Reduced-intensity conditioning followed by T-cell depleted allogeneic SCT for patients with chronic myeloid leukaemia and minimal residual disease at the time of transplant: high risk of molecular relapse. *BMT (EBMT Annual Meeting Abstracts)* 37:P754, 2006
75. Ringhoffer S, Bunjes D, Wenzel P, Wiesneth M, Greiner J, Ringhoffer M. Rapid and economical determination of the sjTREC / DbJb-TREC ratio by a multiplex-nested real-time polymerase chain reaction assay. *BMT (EBMT Annual Meeting Abstracts)* 37:P407, 2006

76. Giannopoulos K, Rolinski J, Dmoszynska A, Hus I, Greiner J, Li L, Döhner H, Schmitt M. RHAMM/CD168 as a new potential target for immunotherapy of B-CLL patients. 3rd Int. Symposium on the Clinical Use of Cellular Products and Cellular Therapy, Regensburg, A26, 2005
77. Giannopoulos K, Li L, Rolinski J, Dmoszynska A, Tabarkiewicz J, Wojas K, Hus I, Greiner J, Döhner H, Schmitt M. Expression of RHAMM/CD168, fibromodulin, survivin, OFAiLRP and hTERT as potential immunotherapeutical targets in patients with B-cell chronic lymphocytic leukaemia. CIMT, 3rd Annual Meeting, Mainz, P22, 2005
78. Schmitt M, Li L, Ringhoffer M, Giannopoulos K, Döhner H, Greiner J. RHAMM/CD168 is a novel target of immunotherapies for patients with acute myeloid leukemia (AML). CIMT, 3rd Annual Meeting, Mainz, P24, 2005
79. Giannopoulos K, Hus I, Li L, Bojarska-Junak A, Greiner J, Rolinski J, Dmoszynska A, Doehner H, Schmitt M. The Receptor for Hyaluronic Acid Mediated Motility (RHAMM/CD168) Is a Potential Target for Immunotherapy of Patients with B-Cell Chronic Lymphocytic Leukemia. Blood (ASH Annual Meeting Abstracts) 106: 53, 2005
80. Greiner J, Giannopoulos K, Li L, Liebisch P, Wendl C, Chen J, Ringhoffer M, Guillaume P, Ritter G, Doehner H, Schmitt M. RHAMM/CD168-R3 Peptide Vaccination of HLA-A2+ Patients with Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS) and Multiple Myeloma (MM). Blood (ASH Annual Meeting Abstracts) 106: 2781, 2005
81. Greiner J, Li L, Giannopoulos K, Brunner C, Döhner K, Döhner H, Schmitt M. Chronic Myeloid Leukemia (CML) Cells Express Tumor Associated Antigens Eliciting Specific CD8+ T Cell Responses Despite of Deficient Expression of Costimulatory Molecules. Blood (ASH Annual Meeting Abstracts) 106: 2886, 2005
82. Greiner J, Li L, Ringhoffer M, Giannopoulos K, Guillaume P, Ritter G, Döhner H, Schmitt M. RHAMM/CD168-R3 peptide vaccination of HLA-A2+ patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS) and multiple myeloma (MM). Onkologie 28 (Suppl.3): 37, [DGHO] 2005
83. Hus I, Rolinski J, Tabarkiewicz J, Wojas K, Bojarska-Junak A, Greiner J, Giannopoulos K, Dmoszynska A, Schmitt M. Allogeneic dendritic cells pulsed with tumor lysates or apoptotic bodies as immunotherapy for patients with early stage B-cell chronic lymphocytic leukemia (B-CLL). Onkologie 28 (Suppl.3): 257, [DGHO] 2005
84. Giannopoulos K, Li L, Bojarska-Junak A, Roliński J, Dmoszynska A, Hus I, Greiner J, Renner C, Döhner H, Schmitt M. Expression of RHAMM/CD168 and other tumor associated antigens in patients with B-cell chronic lymphocytic leukaemia. Onkologie 28 (Suppl.3): 260, [DGHO] 2005

85. Greiner J, Li L, Ringhoffer M, Barth T, Giannopoulos K, Guillaume P, Ritter G, Döhner H, Schmitt M. Characterization of peptide-epitopes of the receptor for hyaluronic acid mediated motility (RHAMM/CD168) recognized by specific CD8+ effector T cells of HLA-A2 positive patients with acute myeloid leukemia (AML). *Onkologie* 28 (Suppl.3): 348, [DGHO] 2005
86. Li L, Reinhardt P, Schmitt A, Greiner J, Ringhoffer M, Schrezenmeier H, Döhner H, Wiesneth M, Schmitt M. Vaccination of patients with acute myeloid leukemia by blast-derived dendritic cells eliciting in vivo specific cytotoxic T cell and type 1 helper cell responses. *Onkologie* 28 (Suppl.3): 357, [DGHO] 2005
87. Greiner J, Li L, Giannopoulos K, Brunner C, Döhner K, Döhner H, Schmitt M. Chronic myeloid leukemia cells express tumor associated antigens eliciting specific CD8+ T cell responses despite of deficient expression of costimulatory molecules. *Onkologie* 28 (Suppl.3): 666, [DGHO] 2005
88. Greiner J, Giannopoulos K, Li L, Liebisch P, Wendl C, Chen J, Guillaume P, Ritter G, Döhner H, Schmitt M. Clinical and Immunological responses to RHAMM/CD168-R3 peptide vaccination in patients with acute myeloid leukemia, myelodysplastic syndrome and multiple myeloma. *Cancer Vaccines Conference 2005* (Cancer Research Institute New York), P-105, 2005
89. Giannopoulos K, Rolinski J, Bojarska-Junak A, Dmoszynska A, Hus I, Greiner J, Döhner H, Schmitt M. RHAMM/CD168 as a new potential target for immunotherapy of CLL patients. *Acta Haematologica Polonica* 36:192, 2005 Annual Meeting of the Polish Society for Immunohematology, Lublin 2005
90. Ringhoffer M, Wiesneth M, Harsdorf S von, Schmitt M, Greiner J, Zenz T, Stilgenbauer S, Döhner H, Bunjes D. Reduced-intensity conditioning followed by T-cell depleted allogeneic SCT for chronic myeloid leukaemia patients with minimal residual disease at the time of transplant: early results of a pilot study. *BMT (EBMT Annual Meeting Abstracts)* 35:R1176 2005
91. Greiner J, Ringhoffer M, Li L, Barth T, Wölfel T, Döhner H, Schmitt M. The receptor for hyaluronic acid mediated motility (RHAMM/CD168) is a leukemia associated antigen eliciting both humoral and cellular immune responses in patients with acute myeloid leukemia (AML). *CIMT, 2nd Annual Meeting, Mainz, 2004*
92. Schmitt M, Li L, Ringhoffer M, Barth T, Wiesneth M, Döhner H, Greiner J. Characterization of T cell epitopes of the receptor for hyaluronic acid mediated motility (RHAMM/CD168) in acute myeloid leukemia. *Blood*. 2004; 104:2540 (abstract). Annual Meeting of the American Society of Hematology, San Diego, 2004
93. Greiner J, Ringhoffer M, Li L, Barth T, Wölfel T, Döhner H, Schmitt M. The receptor for hyaluronic acid mediated motility (RHAMM/CD168) is a leukemia associated antigen eliciting both humoral and cellular immune responses in patients with acute myeloid leukemia (AML). *Onkologie* 27 (Suppl.3): 071 [DGHO] 2004

94. Greiner J, Wiehe J, Wiesneth M, Zwaka T, Schwarz K, Schmitt M, Döhner H, Hombach V, Torzewski J. Efficient transient genetic labeling of human CD34 positive hematopoietic stem cells. *Onkologie* 27 (Suppl.3): 0247 [DGHO] 2004
95. Giannopoulos K, Greiner J, Rolinski J, Dmoszynska A, Hus I, Döhner H, Schmitt M. The mRNA expression of tumor associated antigens (TAAs) in CLL patients. *Onkologie* 27 (Suppl.3): P591 [DGHO] 2004
96. Li L, Reinhardt P, Schmitt A, Greiner J, Ringhoffer M, Döhner H, Wiesneth M, Schmitt M. Dendritic cells generated from acute myeloid leukemia (AML) blasts maintain the expression of leukemia associated antigens. *Onkologie* 27 (Suppl.3): P663 [DGHO] 2004
97. Greiner J, Li L, Brunner C, Wiesneth M, Ringhoffer M, Döhner H, Schmitt M. Differential expression of tumor associated antigens and immuno-stimulatory molecules in chronic myeloid leukemia (CML) cells. *Onkologie* 27 (Suppl.3): P846 [DGHO] 2004
98. Wiesneth M, Greiner J, Torzewski J. Genetische Markierung von hämatopoetischen Stammzellen zum intramyokardialen Nachweis nach in-vivo-Applikation. Wissenschaftliches Symposium des DRK-BSD Baden-Württemberg – Hessen, Haus Bergkranz, Riezlern, 25.06.2004
99. Greiner J, Ringhoffer M, Taniguchi M, Schmitt A, Döhner H, Schmitt M. Leukemia-associated antigens with a high expression frequency in patients with acute myeloid leukemia (AML). *Proc Amer Assoc Cancer Res* (1st ed.) 44: 1856, 2003
100. Greiner J, Hilker J, Prill T, Schwarz K, Wiesneth M, Bienek-Ziolkowski M, Schmitt M, Döhner H, Hombach V, Torzewski J. Transient genetic labeling of human CD34 positive hematopoietic stem cells for autologous in vivo application. 2nd Int. Symp. On the Clinical Use of Cellular Products. *Cellular Therapy*, E1, 2003
101. Schmitt M, Reinhardt P, Li L, Schmitt A, Greiner J, Ringhoffer M, Döhner H, Wiesneth M. Autologous dendritic cell (DC) vaccination of elderly patients with acute myeloid leukemia (AML) results in immunological response. 2nd Int. Symp. On the Clinical Use of Cellular Products. *Cellular Therapy*, B2, 2003
102. Schmitt M, Li L, Reinhardt P, Schmitt A, Greiner J, Ringhoffer M, Wiesneth M, and Döhner H. Autologous dendritic cell (DC) vaccination of elderly patients with acute myeloid leukemia (AML) can elicit a cytotoxic T cell response. *Cancer Immunotherapy [CITM]*, 1st Annual Meeting, P14, 2003
103. Vollmer M, Schmitt A, Greiner J, Reinhardt P, Ringhoffer M, Wiesneth M, Döhner H, Schmitt M. Preservation of HLA and CD86, but loss of CD40 and CD80 on blasts of patients with acute myeloid leukemia (AML). *Onkologie* 25 (Suppl.4): 59 [DGHO] 2002

104. Greiner J, Ringhoffer M, Taniguchi M, Szmaragowska A, Döhner H, Schmitt M. Expression profiles of tumor-associated antigens (TAA) in patients with acute myeloid leukemia (AML). *Onkologie* 25 (Suppl.4): 60 [DGHO] 2002
105. Kirsche H, Greiner J, Gschwend J, Schenk A, Braun S, Szmaragowska A, Hautmann R, Döhner H, Schmitt M, Ringhoffer M. The receptor for hyaluronan mediated motility (RHAMM) is quantitatively overexpressed in renal cell carcinoma and is able to elicit humoral immune responses. *Onkologie* 25 (Suppl.4): 0368 [DGHO] 2002
106. Greiner J, Ringhoffer M, Taniguchi M, Döhner H, Schmitt M. Tumor-associated antigens in myeloid leukemias. *Onkologie* 25 (Suppl.4): 0379 [DGHO] 2002
107. Greiner J, Ringhoffer M, Taniguchi M, Szmaragowska A, Döhner H, Schmitt M. Humoral immune responses to leukemia-associated antigens (LAA) in acute and chronic myeloid leukemias (AML/CML). *Onkologie* 25 (Suppl.4): 0380 [DGHO] 2002
108. Reinhardt P, Schmitt M, Ringhoffer M, Greiner J, Maccari B, Schmitt A, Döhner H, Wiesneth M. Autologous dendritic cells for the treatment of patients with refractory acute myeloid leukemia. *Onkologie* 25 (Suppl.4): 0640 [DGHO] 2002
109. Li L, Schmitt A, Reinhardt P, Ringhoffer M, Greiner J, Wiesneth M, Döhner H, Schmitt M. Reconstitution of CD40 and CD80 in DC generated from AML blasts. 7th International Symposium on Dendritic Cells, Bamberg, 2002
110. Schmitt M, Ringhoffer M, Simikopinko O, Szmaragowska A, Hübsch S, Taniguchi M, Doehner H, Greiner J. Identification of Immunogenic Antigens in Myeloid Leukemias by Serological Screening of Expression Libraries (SEREX). *Proc Am Assoc Cancer Res* 42: 833, 2001
111. Greiner J, Ringhoffer M, Szmaragowska A, Hübsch S, Taniguchi M, Döhner H, Schmitt M. mRNA expression profiles of different relevant tumor-associated antigens in myeloid leukemias. *Onkologie* 23, (Suppl. 6) Vol. 24: 226 [DGHO] 2001
112. Greiner J, Ringhoffer M, Taniguchi M, Szmaragowska A, Eil A, Döhner H, Schmitt M. The receptor for hyaluronic acid mediated motility (RHAMM) is a new immunogenic tumor-associated antigen highly expressed in acute and chronic myeloid leukemia (AML/CML). *Onkologie* 23, (Suppl. 6) Vol. 24: 254 [DGHO] 2001
113. Greiner J, Ringhoffer M, Taniguchi M, Hübsch S, Eil A, Döhner H, Schmitt M. The tumor-associated antigen PRAME is a potential marker for minimal residual disease (MRD) and a candidate for immunotherapy in acute myeloid leukemia (AML). *Onkologie* 23, 25 (Suppl 6) Vol. 24: 258 [DGHO] 2001

114. Ringhoffer M, Greiner J, Gschwend J, Kirsche H, Schenk A, Hübsch S, Szmaragowska A, Hautmann R, Döhner H, Schmitt M. The receptor for hyaluronan mediated motility (RHAMM) is expressed in a high percentage of renal cell carcinoma and is able to elicit humoral immune responses. *Onkologie* 23, 25 (Suppl.6) Vol. 24: 263a, 2001
115. Ringhoffer M, Gschwend J, Schmitt M, Greiner J, Schenk A, Hautmann R, Döhner H. 2nd-line protocol for the treatment of metastatic renal cell carcinoma with a combination therapy containing interleukin-2, interferon-alpha, 13 cis-retinoic-acid (13CRA) and gemcitabine. *Onkologie* 23, 25 (Suppl.6) Vol. 24: 651a [DGHO] 2001
116. Greiner J, Ringhoffer M, Simikopinko O, Szmaragowska A, Maurer U, Bergmann L, Schmitt M. Immunogenic antigens simultaneously expressed in acute myeloid leukemia (AML). *Acta Haematologica* 103 (Suppl.1): 167, 2000
117. Greiner J, Ringhoffer M, Simikopinko O, Szmaragowska A, Döhner H, Schmitt M. Immunogenic antigens characterized in acute myeloid leukemia (AML) and chronic myeloid leukemia (CML). *Onkologie* 23 (Suppl.7): 0321 [DGHO] 2000
118. Schimitzek C, Greiner J, Ringhoffer M, Maurer U, Szmaragowska A, Hübsch S, Taniguchi M, Döhner H, Schmitt M. Quantitative measurement of the mRNA expression of the Wilms tumor gene (WT1) by real time reverse transcriptase polymerase chain reaction (RT-RT-PCR) in leukemia. *Onkologie* 23 (Suppl.7): 0334 [DGHO] 2000
119. Greiner J, Ringhoffer M, Szmaragowska A, Hübsch S, Schimitzek C, Taniguchi M, Döhner H, Schmitt M. Real time reverse transcriptase polymerase chain reaction of minimal residual disease (MRD) in acute myeloid leukemia (AML). *Onkologie* 23 (Suppl.7): 0356 [DGHO] 2000
120. Ringhoffer M, Gschwend J, Schmitt M, Greiner J, Schenk A, Prang J, Simon J, Bergmann L, Hautmann R, Döhner H. 2nd-line protocol for the treatment of refractory metastatic renal cell carcinoma with a combination therapy containing interleukin-2, interferon- α , 13 cis-retinoic-acid (13 CRA) and gemcitabine. *Onkologie* 23 (Suppl.7): 0424 [DGHO] 2000
121. Schmitt M, Hendinger S, Hübsch S, Ringhoffer S, Kirchner D, Hübinger G, Ringhoffer M, Greiner J, Schimitzek C, Taniguchi M, Schneckenburger H. Optoporation as a novel technique of molecule transfer into dendritic cells (DC). *Onkologie* 23 (Suppl.7): 0610 [DGHO] 2000
122. Greiner J, Ringhoffer M, Simikopinko O, Szmaragowska A, Bergmann L, Schmitt M. Characterization of immunogenic antigens in acute myeloid leukemia (AML). *Onkologie* 22 (Suppl.1): 0367 [DGHO] 1999
123. Schmitt M, Greiner J, Ringhoffer M, Nothdurft W, Shiku H, Bergmann L. Aggravation of acute graft-versus-host (GVH) reaction by IL-12 in murine MHC -matched bone marrow transplantation (BMT) is triggered by alloantigen recognition of donor lymphocytes and mediated by Fas ligand, TNF α and interferon gamma (INF γ). *Onkologie* 22 (Suppl.1): 0732 [DGHO] 1999